Sign in to view content

Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials

Carl D. Regillo, MD

Video
Published 2019

Carl D. Regillo, MD, FACS

AMD Neovascular Part I

Related

What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2019
Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results
Jeffrey S. Heier, MD
Annual Meeting Talks
2019
Episode 11: Endophthalmitis after Intravitreal Anti-VEGF Injections with Dr. David Almeida
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more